HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rebecca Redman Selected Research

paritaprevir

3/2019Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II).
4/2018Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
1/2018Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
1/2017Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
1/2016Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
1/2016Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.
1/2016Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
11/2015Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects.
10/2015Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
10/2015Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rebecca Redman Research Topics

Disease

12Infections
03/2019 - 05/2010
9Fibrosis (Cirrhosis)
03/2019 - 10/2015
6Urinary Tract Infections (Urinary Tract Infection)
11/2015 - 01/2009
5Neoplasms (Cancer)
12/2021 - 03/2004
5Chronic Hepatitis C
03/2019 - 06/2015
5Intraabdominal Infections
11/2015 - 01/2009
4Head and Neck Neoplasms (Head and Neck Cancer)
09/2017 - 03/2004
4Healthcare-Associated Pneumonia
04/2013 - 01/2009
3Squamous Cell Carcinoma of Head and Neck
09/2017 - 01/2014
3Virus Diseases (Viral Diseases)
11/2015 - 06/2015
3Ventilator-Associated Pneumonia
11/2012 - 01/2009
3Stomatitis
06/2004 - 08/2002
3Pain (Aches)
06/2004 - 08/2002
2Seizures (Absence Seizure)
08/2009 - 01/2009
1Pancreatic Neoplasms (Pancreatic Cancer)
12/2021
1Glioma (Gliomas)
12/2021
1Squamous Cell Neoplasms (Squamous Cell Cancer)
12/2021
1Hepatitis C
03/2019
1Lymphatic Metastasis
09/2017
1Nasopharyngitis
01/2017
1Anemia
01/2017
1Edema (Dropsy)
01/2016
1Pneumonia (Pneumonitis)
11/2015
1Bacterial Pneumonia
11/2015
1Body Weight (Weight, Body)
08/2015
1Weight Loss (Weight Reduction)
07/2015
1Hypoxia (Hypoxemia)
08/2013
1Carcinoma (Carcinomatosis)
08/2013
1Cystic Fibrosis (Mucoviscidosis)
11/2012
1Critical Illness (Critically Ill)
01/2012
1Chronic Renal Insufficiency
03/2011
1Cross Infection (Nosocomial Infection)
08/2009
1Pyelonephritis
04/2009
1Nausea
03/2004
1Wounds and Injuries (Trauma)
12/2002

Drug/Important Bio-Agent (IBA)

11paritaprevirIBA
03/2019 - 06/2015
11ombitasvirIBA
03/2019 - 06/2015
11DoripenemFDA Link
11/2015 - 01/2009
10Ritonavir (Norvir)FDA Link
03/2019 - 06/2015
7Ribavirin (Virazole)FDA LinkGeneric
03/2019 - 06/2015
6InterferonsIBA
03/2019 - 06/2015
6Antiviral Agents (Antivirals)IBA
03/2019 - 11/2015
4glecaprevir and pibrentasvirIBA
04/2018 - 01/2018
4Protease Inhibitors (Protease Inhibitor)IBA
01/2018 - 10/2015
4Carbapenems (Carbapenem Antibiotics)IBA
05/2010 - 01/2009
3P-300IBA
04/2018 - 01/2018
3RNA (Ribonucleic Acid)IBA
01/2016 - 06/2015
3antimicrobial peptide IB-367 (iseganan)IBA
06/2004 - 08/2002
2BilirubinIBA
01/2017 - 01/2016
2Pharmaceutical PreparationsIBA
01/2016 - 10/2015
1LY3300054IBA
12/2021
1130-nm albumin-bound paclitaxelIBA
12/2021
1Immune Checkpoint InhibitorsIBA
12/2021
1GemcitabineFDA Link
12/2021
1Antineoplastic Agents (Antineoplastics)IBA
12/2021
1Cisplatin (Platino)FDA LinkGeneric
12/2021
1SofosbuvirIBA
03/2019
1glecaprevirIBA
01/2018
1Proteins (Proteins, Gene)FDA Link
01/2018
1pibrentasvirIBA
01/2018
1Hepatitis C AntibodiesIBA
01/2016
1Calcium Channel Blockers (Blockers, Calcium Channel)IBA
01/2016
1A-factor (Streptomyces)IBA
01/2014
13- (3- pyridinyl)- 1- (4- pyridinyl)- 2- propen- 1- oneIBA
08/2013
1Phosphofructokinase-2 (Phosphofructokinase 2)IBA
08/2013
1PFK15IBA
08/2013
1Glucose (Dextrose)FDA LinkGeneric
08/2013
1Imipenem Drug Combination Cilastatin (Primaxin)FDA Link
11/2012
1FluoroquinolonesIBA
05/2010
1Ceftazidime (Fortum)FDA LinkGeneric
05/2010
1Ciprofloxacin (Cipro)FDA LinkGeneric
05/2010
1beta-Lactamases (beta-Lactamase)IBA
05/2010
1Levofloxacin (Levaquin)FDA Link
04/2009
1GABA Receptors (GABA Receptor)IBA
01/2009
1ImipenemFDA Link
01/2009
1Meropenem (Merrem)FDA LinkGeneric
01/2009
1Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric
01/2009
1Opiate AlkaloidsIBA
06/2004
1Analgesics (Analgesic Drugs)IBA
06/2004
1SolutionsIBA
03/2004
1Antimicrobial PeptidesIBA
08/2002

Therapy/Procedure

6Therapeutics
12/2021 - 06/2004
4Radiotherapy
01/2016 - 08/2002
2Duration of Therapy
03/2019 - 01/2018
2Continuous Renal Replacement Therapy
01/2012 - 03/2011
2Drug Therapy (Chemotherapy)
06/2004 - 08/2002
1Neck Dissection (Radical Neck Dissection)
09/2017
1Neoadjuvant Therapy
09/2016
1Conformal Radiotherapy
01/2016
1Palliative Care (Palliative Therapy)
01/2016
1Diet Therapy (Therapy, Diet)
07/2015
1Intravenous Infusions
03/2011
1Artificial Respiration (Mechanical Ventilation)
12/2002